|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the CNRS UMR 1598, Interactions moléculaires
et cancer, Institut Gustave Roussy, Villejuif, France; Laboratoire de
cytométrie, Institut de recherche sur le cancer, rue Guy Moquet,
Villejuif, France; CNRS UMR 8532, Physicochimie et pharmacologie des
macromolécules biologiques, Institut Gustave Roussy, Villejuif,
France.
Following stress signals, the p53 tumor suppressor protein plays a
critical role in regulation of cell proliferation, mainly through
induction of growth arrest or apoptosis. Therefore, this protein needs
to be strictly regulated and numerous studies have shown that the MDM2
protein is an essential element for p53 regulation in normal cells and,
most importantly, that overexpression of MDM2 is responsible for p53
inactivation in various types of tumors. A previous study showed that
this is the case in some Burkitt lymphoma (BL) cell lines, where
enhanced translation of mdm2 messenger RNA results in overexpression of
the protein that complexes and inactivates wild-type p53. To further
investigate the role of the p53/MDM2 complex in these BL cells, as well
as in other lymphoid cells that do not overexpress MDM2, this study
used antisense oligodeoxynucleotides directed either against mdm2 or
against p53. Results show that the mdm2 antisense oligodeoxynucleotide induces apoptosis of cells that express a high or low level of MDM2
protein, only if they contain wild-type p53. Moreover, apoptosis is
independent of the accumulation of p53 following mdm2 antisense treatment. Finally, the p53 antisense oligodeoxynucleotide, which inhibits the expression of wild-type p53, also induces a decrease of
the MDM2 level in cells, whether or not they overexpress this protein,
and causes apoptosis of these cells. These results indicate that
decreasing the MDM2 protein level by directly or indirectly targeting
its biosynthesis is a potent tool for the induction of apoptosis.
(Blood. 2001;97:1043-1049) The tumor suppressor p53 is a multifunctional
protein that has a critical role in various pathways controlling
cellular responses to stress signals.1,2 The main
mechanism whereby this molecule controls cell growth is through
transactivation of genes involved either in cell cycle arrest
(p21WAF1, 14-3-3 MDM2 was originally identified as one of the genes amplified on double
minute particles in a spontaneously transformed mouse 3T3 cell
line.6 The oncogenic potential of this molecule was then
confirmed, when it was shown that specific overexpression of the
mdm2 gene increases the tumorigenic properties of mouse or rat tumor cell lines7,8 and when it was observed that the mdm2 gene is amplified in a variety of human tumors, the
highest frequency being in soft-tissue tumors and osteosarcomas
(reviewed in reference 9).
Although recent data obtained with mdm2 transgenic, p53-null mice
indicate that MDM2 could be oncogenic by itself,10,11 it
is generally assumed that the transforming properties of this molecule
are due to its ability to inhibit the tumor suppressor function of p53
(reviewed in references 12-14). MDM2 negatively regulates p53 function
through its ability to bind to the N-terminal transactivation domain of
p53,15,16 but recent reports have also shown that it is
involved in the degradation of p53. Indeed, MDM2 is apparently able to
transport p53 from the nucleus to the cytoplasm17,18 where
its ubiquitin-ligase activity19 contributes to the
proteasome-mediated degradation of p53. Because the
mdm2 gene itself is inducible by p53,20 a
functional feedback loop exists between these 2 molecules, with p53
inducing expression of MDM2 and MDM2 inhibiting p53
function.21 In addition to being oncogenic when
overexpressed, the ability of MDM2 to strictly regulate p53 makes it a
critical element for the fate of normal cells, as demonstrated by
studies showing that mdm2-deficient mice can only develop in a p53-null
background.22,23
Burkitt lymphoma (BL) is a B-cell neoplasm characterized by chromosomal
translocations affecting the c-myc locus and leading to the
constitutive activation of this oncogene (reviewed in references 24 and
25). In addition to the activation of c-myc, the
inactivation of p53 seems to be an important step in the development of
this tumor. Indeed, studies have shown that, among hematologic
malignancies, one of the highest incidences of p53 mutations is
observed in BL (33%-40% of biopsies26,27 and 60%-83% of
BL-derived cell lines28,29), and that these mutations
result in the inactivation of the protein.30 It was,
therefore, proposed that p53 inactivation contributes to the
transformation of BL cells, most probably at a stage subsequent to
c-myc activation.31 This hypothesis is supported by our recent finding that, in some BL cell lines,
inactivation of p53 can also result from the overexpression of MDM2. Of
20 BL cell lines studied, 4 exhibited a wild-type p53 protein
associated with high levels of MDM2 and these cells, similarly to p53
mutated BL cell lines, neither showed a G1 arrest nor
underwent apoptosis following To further investigate the role of the p53/MDM2 complex we decided to
use antisense oligodeoxynucleotides directed against the corresponding
transcripts. These experiments were performed in cells presenting
different p53 and MDM2 status: BL cells containing wild-type p53 and
overexpressing MDM2; cells with inactivated p53 (p53 mutated BL cells)
or without p53 expression (osteosarcoma cells) and no overexpression of
MDM2; and lymphoblastoid cells with wild-type p53 and no overexpression
of MDM2. Here, we report that the mdm2 antisense (mdm2 AS) induces
apoptosis only in cells carrying a wild-type p53 and that the cell
death does not necessarily correlate with an accumulation of p53.
Moreover, we also demonstrate that treatment of cells containing
wild-type p53 with the p53 antisense (p53AS) induces a decrease in both
p53 expression and MDM2 level (independent of the basal level of
expression of this protein) and causes apoptosis of these cells.
Cell culture and transfections
For transfection experiments, Saos-2 cells were seeded at
1 × 106 cells per 10-cm dish and after 18 to 24 hours they were transfected by the calcium phosphate
method33 with the pCMV-mdm2 expression plasmid34 or the pCMV empty vector (both kindly supplied by Dr D. Trouche (Toulouse, France), which harbor the G418
resistance gene. The cells were collected 48 hours after transfection
and seeded in 96-well plates (at 1000 and 10 000 cells/well) in DMEM containing G418 (600 µg/mL). Expression of MDM2 was tested by Western
blot analysis of cells obtained from wells where only one colony was growing.
mdm2 and p53 oligodeoxynucleotides
Electropermeabilization Electropermeabilization of the cells was performed with a PS-15 electropulsator (Jouan, Saint-Herblain, France). Electrodes were 2 stainless steel plates that were 2 mm apart. Cells were electroporated in 50µL RPMI 1640 medium containing 1% FCS, at a concentration of 2 × 106 cells/50µL, with 80µM oligodeoxynucleotides. Cells were deposited between the electrodes and immediately exposed to 8 square-wave electric pulses of 100 µs and 280 V delivered at a frequency of 1 Hz. Immediately after electroporation, cells were resuspended in 4 mL RPMI 1640 medium containing 5% FCS and cultured at 37°C.Western blot analysis Cell pellets, resuspended in lysis buffer (50 mM Tris-HCl, pH 6.8, 2% sodium dodecyl sulfate [SDS], 100 mM DTT, 1 mM aprotinin), were sonicated and then incubated for 10 minutes at 4°C. Lysates were then diluted in loading buffer (50 mM Tris-HCl, pH 7.4, 2% SDS, 9% glycerol, 0.7 M -mercaptoethanol, 0.005% bromophenol blue) and
proteins were separated on a SDS-7.5% polyacrylamide gel
electrophoresis [PAGE]. After electrophoresis, proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA) by a semidry electroblotting system (Millipore). After blocking with phosphate-buffered saline (PBS) containing 3%
nonfat dry milk and 2% glycine, blots were probed with either an
anti-MDM2 monoclonal antibody (mAb) (IF2, Oncogene Research, Boston,
MA), or an anti-p53 mAb (DO1, Santa Cruz Biotechnology, Santa
Cruz, CA) or an anti-PARP mAb (C2-10, Oncogene Research) or an
anti- actin mAb (AC-74, Sigma, L'isle d'Abeau Chesnes, France). All these antibodies were used at a concentration of 2 µg/mL. After incubation with a rabbit antimouse IgG (ICN, Costa Mesa,
CA), the blots were revealed with [125I]-protein
A (Amersham, Orsay, France) and submitted to autoradiography.
Induction of apoptosis Apoptosis was either induced by cytotoxic agents or by -irradiation. Saos-2 parental cells (5 × 105)
or the various stable mdm-2 transfectants were taken in 4 mL DMEM
containing okadaïc acid at 20 nM or doxorubicin at 100 ng/mL and incubated for 48 hours at 37°C ; 5 × 105
cells were irradiated at room temperature (8 Gy) using a
137Cs source delivering 1.57 Gy/min and then incubated
for 72 hours at 37°C. All cells (adherent and detached) were then
collected and cell viability was measured.
Cell viability After treatment, cells were centrifuged, resuspended in HEPES buffer (10 mM HEPES/NaOH, pH7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2) containing 2.5 µg/mL fluorescein isothiocyanate (FITC)-labeled annexin V (Euromedex, Mundolsheim, France) and incubated at 4°C for 5 minutes. They were then washed twice in HEPES buffer and propidium iodide (10 µg/mL) was added immediately before analyzing the cells with a FACSCalibur (Becton Dickinson, San Jose, CA) cytofluorometer. The percentage of apoptotic cells is: % annexin V (+) PI( ) + % annexin V(+) PI(+).
Effects of mdm2 AS on MDM2 and p53 protein levels We have previously reported that p53 is functionally inactivated in 4 BL cell lines (BL2, Ly47, Ly91, and Seraphina), which overexpress MDM2 protein.32 To further study the function of MDM2, we then decided to treat, with an mdm2 AS oligodeoxynucleotide, various cell lines having different MDM2 and p53 status: BL2 (BL cells, MDM2 high, wild-type p53), Ramos (BL cells, MDM2 low, mutant p5329), Priess (lymphoblastoid cells, MDM2 low, wild-type p53), and Saos-2 (osteosarcoma cells, MDM2 low, p53-null37). The levels of expression of MDM2 and p53 were tested by Western blot analysis and are shown in Figure 1. As expected, the mutant p53 is greatly accumulated in Ramos cells.
An AS phosphorothioate oligodeoxynucleotide targeting the AUG initiation codon of mdm2 messenger RNA (mRNA) (mdm2 AS) and the corresponding scrambled control oligodeoxynucleotide (mdm2 SC), were introduced into cells by electropermeabilization. Our protocol using square-wave electric pulses, which is a modification of the classical electroporation technique, was chosen because it allows efficient delivery of various types of molecules, including oligonucleotides,38 into different types of cells with minimal damages.39-41 Before electropermeabilization, cells were taken in 50µL RPMI 1640 containing 1% FCS, mixed with mdm2 AS or SC (at a concentration of 80 µM) and immediately submitted to the electric pulses (8 pulses of 100µs at 280 V). They were then resuspended in 4 mL RPMI 1640 containing 5% FCS (being therefore in contact with the oligodeoxynucleotides at a concentration of 1 µM). After 4 hours of incubation at 37°C, the MDM2 protein expression was
analyzed by Western blot using IF2 mAb and bands were quantified by
densitometry (following normalization for
Effects of mdm2 AS on cell viability We then examined the effects of the mdm2 AS on cell viability. At various times after electropermeabilization (8, 12, 18, and 24 hours), cells were labeled with annexin V-FITC and propidium iodide (PI) and analyzed with a FACSCalibur flow cytometer. No effects on cell viability were observed after 8, 12, and 18 hours (data not shown), whereas apoptotic cells could be seen in some samples 24 hours after treatment. For BL2 cells, it can be seen in Table 1 that treatment with the mdm2 AS strongly increased the number of apoptotic cells, which increased from 20% ± 3% (for the cells electroporated with medium) and 25% ± 8% (for the mdm2 SC-treated cells) to 54% ± 9%. Because the Priess cells do not overexpress MDM2 and do not accumulate p53 after AS treatment, we were surprised to see that the mdm2 AS also increased the mortality of the Priess cells (from 28% ± 1% and 33% ± 3% in the control cells to 44% ± 2%). In contrast, no effect of the mdm2 AS could be observed on the viability of Ramos or Saos-2 cells.
To confirm that the AS-treated cells were truly dying by apoptosis, we
also measured the cleavage of the poly-ADP ribose polymerase (PARP), an
enzyme involved in DNA repair, which is generally cleaved during
apoptosis.42 The expression of the 116- kd native PARP protein and its 85-kd cleavage product were analyzed by Western blot
using C2-10 mAb. The PARP cleavage product was clearly visible in BL2
and Priess cells electroporated with mdm2 AS, whereas it was not
detected in Ramos and Saos-2 cells (Figure
3).
These results indicate that mdm2 AS induces apoptosis of the cells that contain MDM2 protein (whether this protein is overexpressed or not) and wild-type p53 (whether this protein accumulates after AS treatment or not) but have no effects on the viability of the cells that contain MDM2 and mutated p53 or MDM2 and no p53. Effects of p53 AS on p53 and MDM2 protein levels Because the mdm2 AS-induced apoptosis occurred only in wild-type p53 lymphoid cell lines but seemed to be independent of the level of this protein, we decided to use p53 AS to further investigate the role of this protein. First, we tested the effects of a previously described p53 AS36 on the p53 and the MDM2 protein levels. Four hours after electropermeabilization of p53 AS, p53 SC (each at 80 µM during the electroporation and then at 1 µM) or medium, p53 and MDM2 expression were tested by Western blot analysis and the bands were quantified by densitometry (following normalization for-actin
expression). It can be seen in Figure 4
that p53 AS substantially reduced (as compared to cells electroporated
with medium or p53 SC) the expression of p53 in BL2 and Priess cells but had no effect in Ramos cells. It is possible, however, that this
apparent lack of inhibition was only due to the strong accumulation of
p53 in these cells, which could mask an effect of the p53 AS on the
newly synthesized protein. In Figure 4, it can also be seen that the
p53 AS induced a clear decrease of the MDM2 protein level in BL2 and
Priess cells. In contrast, no specific change in MDM2 level could be
observed after p53 AS in Ramos cells.
Effects of p53 AS on cell viability The viability of the cells treated for 24 hours with p53 AS and p53 SC was then examined by labeling the cells with annexin V-FITC and PI. It can be seen in Table 2 that the p53 AS increased the mortality of BL2 and Priess cells (43% ± 2% and 61% ± 1%, respectively) as compared to cells treated with p53 SC (28% ± 3% and 41% ± 4%) or medium (14% ± 1% and 27% ± 2%). In contrast, no changes were observed for Ramos cells. From these results, it can be concluded that p53 AS induces apoptosis of the cells when a concomitant decrease of wild-type p53 and MDM2 protein levels are observed.
Susceptibility to apoptosis of MDM2-overexpressing Saos-2 cells Our results show that a decrease of the MDM2 protein level triggers an apoptotic process that is not correlated to the level of the p53 protein but is apparently dependent of the p53 activity. To confirm these data, we decided to check whether the level of MDM2 by itself could modulate the susceptibility of the cells to apoptosis by submitting a series of mdm2 transfectants made in the p53-null Saos-2 cells to various apoptotic stimuli. Saos-2 cells were transfected with an expression plasmid containing the human mdm2 cDNA (pCMV-neo-mdm2) or with the empty vector and after 5 weeks of culture in the selection media (containing G418) expression of MDM2 was tested by Western blot analysis. Among the 20 MDM2-transfectants tested, 5 were chosen because they greatly overexpressed MDM2. None of the control transfectants overexpressed MDM2 (data not shown). Stability of the MDM2 expression was then checked by Western blot every 2 weeks. Cells were treated for 48 hours with okadaic acid (20 nM) or doxorubicin (100 ng/mL) or they were exposed to 8 Gy of-radiation and then cultured for 72 hours.
As shown in Table 3, okadaic acid,
doxorubicin, and -radiation induced similar rates of apoptosis in
the MDM2-overexpressing transfectants and in the control transfectants.
The PARP cleavage was tested for most of the transfectants treated by
okadaic acid, doxorubicin, or -radiation. Similar data were
obtained, whether or not the cells overexpressed MDM2 (data not shown).
These results indicate that overexpression of MDM2 in the absence of
p53 does not confer to cells an increased resistance to various types
of apoptotic stimuli.
In this study, we have shown that an antisense oligodeoxynucleotide, which targets the mdm2 gene and is able to specifically reduce the level of the protein, induces apoptosis of cells only when they contain wild-type p53. We have also shown that the inhibition of MDM2 may or may not correlate with an accumulation of p53. We observed that treatment with the mdm2 AS induces accumulation of p53 in BL2 cells, which overexpress MDM2, but not in Priess lymphoblastoid cells, which express a low level of MDM2. It is therefore likely that these results are due to the ability of MDM2 to target p53 degradation. Indeed, it has been shown that, when the 2 proteins are complexed, MDM2 promotes the rapid degradation of p53 via the proteasome pathway.43,44 The exact mechanism is not known, but recent reports indicate that MDM2 is apparently able to fulfill 2 different functions: it shuttles p53 from the nucleus to the cytoplasm17,18 where it participates in the ubiquitination of p53 via its ubiquitin-ligase activity.19 It can be assumed that in BL2 cells that contain a large amount of MDM2, p53 is actively degraded and that a decrease in the level of MDM2 will slow down this degradation process and result in the accumulation of p53. This hypothesis is supported by our observation that, in BL2 cells, p53 accumulation is not due to a transcriptional mechanism because p53 mRNA level was not increased after mdm2 AS treatment (data not shown). This hypothesis also implies that in Priess cells where the basal level of MDM2 is low, its decrease does not modulate the degradation of p53. Previous reports have also examined the level and the functionality of p53 after AS inhibition of MDM2 expression. Chen and coworkers reported the accumulation/activation of p53 in various tumor cell lines, whether or not these cells overexpressed MDM2,45 and Teoh and associates46 observed an activation of p53 without concomitant stabilization in cells overexpressing MDM2. Together with ours, these results suggest that the regulation of p53 level after AS inhibition of MDM2 expression depends on the cell type and that this regulation probably involves other proteins, such as, for example, p19ARF, Rb, or p300, which are known to form complexes with p53 and MDM2 and to modulate their stability and function.47-49 Our data showing that a decrease in the MDM2 level only results in
apoptosis of cells containing wild-type p53, as well as other studies
demonstrating that disruption of the p53/MDM2 complex (triggered by
peptide homologues of p53 that bind to MDM250,51) also
induces growth arrest or apoptosis, certainly reinforce the hypothesis
that MDM2 is an important modulator of the p53-mediated apoptosis.
Furthermore, our results demonstrate that in absence of p53 the MDM2
level cannot influence the apoptotic process, because we showed that
various transfectants of a p53-null cell line, whether or not they
overexpress MDM2, are similarly sensitive to various apoptotic stimuli.
Because it has been shown recently that MDM2 can interact with p73 Finally and most interestingly, we have also demonstrated that, if apoptosis triggered by inhibition of MDM2 certainly depends on p53 activation, this activation is not always correlated with an accumulation of the protein and can even be observed after a decreased expression of p53. Indeed, we have shown that treatment of cells containing wild-type p53 with a p53 AS results in a specific inhibition of p53 expression but also in a decreased level of MDM2 and, subsequently, in the apoptosis of the cells. In normal cells, p53 is a transcription factor that has an important role in response to stress signals. After DNA damage or hypoxia, for example, p53 induces cell cycle arrest or apoptotic cell death and thus contributes to the elimination of cells containing damaged DNA (reviewed in references 3 and 53). Oncogenic transformation, therefore, often involves the inactivation of this molecule, either by mutation or by formation of complexes with other proteins such as MDM2.1,4,5 Among the multitude of studies carried out to better understand the role of p53 protein in transformation, several have been performed with antisense oligodeoxynucleotides in cells containing either a mutated or a wild-type p53. Although some authors showed that inhibition of p53 expression results in enhanced proliferation of certain tumor cell lines,36,54 several others reported that treatment with p53 AS induces growth inhibition or cytotoxicity.55,56 Very interestingly and unexpectedly, most of these reports underlined that these effects were observed in both mutant and wild-type p53-containing cells.57-59 Unfortunately, none of these studies analyzed the effects on the p53 AS on the level of MDM2, but our data suggest that, in cells expressing wild-type p53, it is the decreased level of MDM2 induced by the inhibition of p53 that is responsible for the growth inhibition or the cell death. The observation that inhibition of p53 expression is accompanied, in
BL2 and Priess cells, by a decreased level of MDM2, suggests that in
these cells the level of MDM2 is, at least partly, regulated by p53.
For BL2 cells, where we have shown previously that p53 is inactivated
(following Taken together our results obtained after exposure to
We are grateful to Annick Harel-Bellan, Christian Jaulin, and Marc Lipinski for helpful discussions. We also thank Colin Robert Gardner for his careful editing of the manuscript.
Submitted November 22, 1999; accepted October 9, 2000.
Supported in part by grants from the Ligue Nationale Française contre le Cancer, the Association pour la Recherche sur le Cancer (ARC 6915), the Fondation pour la Recherche Medicale, and the Fondation de France (comité leucémie).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Joëlle Wiels, Interactions moléculaires et cancer CNRS UMR 1598, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France; e-mail: wiels{at}igr.fr.
1. Prives C, Hall PA. The p53 pathway. J Pathol. 1999;187:112-126[CrossRef][Medline] [Order article via Infotrieve]. 2. Almog N, Rotter V. An insight into the life of p53: a protein coping with many functions! Review of the 9th p53 Workshop, Crete, May 9-13, 1998. Biochim Biophys Acta. 1998;1378:R43-R54[Medline] [Order article via Infotrieve]. 3. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol. 1998;8:345-357[CrossRef][Medline] [Order article via Infotrieve].
4.
Greenblatt MS, Bennett WP, Hollstein M, Harris CC.
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Cancer Res.
1994;54:4855-4878
5.
Hainaut P, Hernandez T, Robinson A, et al.
IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools.
Nucleic Acids Res.
1998;26:205-213 6. Cahilly-Snyder L, Yang-Feng T, Franke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet. 1987;13:235-244[CrossRef][Medline] [Order article via Infotrieve]. 7. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991;10:1565-1569[Medline] [Order article via Infotrieve].
8.
Finlay CA.
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Mol Cell Biol.
1993;13:301-306
9.
Momand J, Jung D, Wilczynski S, Niland J.
The MDM2 gene amplification database.
Nucleic Acids Res.
1998;26:3453-3459
10.
Lundgren K, Montes de Oca Luna R, McNeill YB, et al.
Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.
Genes Dev.
1997;11:714-725
11.
Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A.
Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis.
Proc Natl Acad Sci U S A.
1998;95:15608-15612 12. Piette J, Neel H, Maréchal V. Mdm2: keeping p53 under control. Oncogene. 1997;15:1001-1010[CrossRef][Medline] [Order article via Infotrieve]. 13. Haines DS. The mdm2 proto-oncogene. Leuk Lymphoma. 1997;26:227-238[Medline] [Order article via Infotrieve]. 14. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55:96-107[CrossRef][Medline] [Order article via Infotrieve]. 15. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237-1245[CrossRef][Medline] [Order article via Infotrieve]. 16. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993;362:857-860[CrossRef][Medline] [Order article via Infotrieve]. 17. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 1998;17:554-564[CrossRef][Medline] [Order article via Infotrieve].
18.
Tao W, Levine AJ.
Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.
Proc Natl Acad Sci U S A.
1999;96:3077-3080 19. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420:25-27[CrossRef][Medline] [Order article via Infotrieve]. 20. Barak Y, Juven T, Haffner R, Oren M. Mdm2 expression is induced by wild-type p53 activity. EMBO J. 1993;12:461-468[Medline] [Order article via Infotrieve].
21.
Wu X, Bayle JH, Olson D, Levine AJ.
The p53-mdm2 autoregulatory feedback loop.
Genes Dev.
1993;7:1126-1132 22. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995;378:203-206[CrossRef][Medline] [Order article via Infotrieve]. 23. Jones SN, Roe AR, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378:206-208[CrossRef][Medline] [Order article via Infotrieve]. 24. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res. 1990;55:133-270[Medline] [Order article via Infotrieve]. 25. Bornkamm GW, Polack A, Eick D. c-myc deregulation by chromosomal translocation in Burkitt's lymphoma. In: Klein G, ed. Cellular Oncogene Activation. New York: Marcel Dekker; 1988:223. 26. Kornblau SM, Goodacre A, Cabanillas F. Chromosomal abnormalities in adult non-endemic Burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature. Hematol Oncol. 1991;9:63-78[Medline] [Order article via Infotrieve].
27.
Imamura J, Miyoshi I, Koeffler HP.
p53 in hematologic malignancies.
Blood.
1994;84:2412-2421 28. Wiman KG, Magnusson KP, Ramqvist T, Klein G. Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene. 1991;6:1633-1639[Medline] [Order article via Infotrieve]. 29. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 1991;10:2879-2887[Medline] [Order article via Infotrieve].
30.
Vousden KH, Crook T, Farrell PJ.
Biological activities of p53 mutants in Burkitt's lymphoma cells.
J Gen Virol.
1993;74:803-810
31.
Gutierrez MI, Bhatia K, Cherney B, Capello D, Gaidano G, Magrath I.
Intraclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma.
Ann Oncol.
1997;8:987-994 32. Capoulade C, Bressac-de Paillerets B, Lefrere I, et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene. 1998;16:1603-1610[CrossRef][Medline] [Order article via Infotrieve]. 33. Graham FL, van der Eb AJ. Transformation of rat cells by DNA of human adenovirus 5. Virology. 1973;54:536-539[CrossRef][Medline] [Order article via Infotrieve]. 34. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature. 1995;375:691-694[CrossRef][Medline] [Order article via Infotrieve]. 35. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358:80-83[CrossRef][Medline] [Order article via Infotrieve].
36.
Bi S, Lanza F, Goldman JM.
The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoeisis.
Cancer Res.
1994;54:582-586
37.
Masuda HM, Miller C, Koeffler HP, Battifora H, Cline MJ.
Rearrangement of the p53 gene in human osteogenic sarcomas.
Proc Natl Acad Sci U S A.
1987;84:7716-7719 38. Barre FX, Mir LM, Lecluse Y, Harel-Bellan A. Highly efficient oligonucleotide transfer into intact yeast cells using square-wave pulse electroporation. Biotechniques. 1998;25:294-296[Medline] [Order article via Infotrieve]. 39. Orlowski S, Mir LM. Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochim Biophys Acta. 1993;1154:51-63[Medline] [Order article via Infotrieve]. 40. Mir LM, Glass LF, Sersa G, et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer. 1998;77:2336-2342[Medline] [Order article via Infotrieve]. 41. Singh BN, Dwivedi C. Antitumor drug delivery by tissue electroporation. Anticancer Drugs. 1999;10:139-146[Medline] [Order article via Infotrieve].
42.
Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM.
Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant.
J Biol Chem.
1998;273:33533-33539 43. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299-303[CrossRef][Medline] [Order article via Infotrieve]. 44. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296-299[CrossRef][Medline] [Order article via Infotrieve]. 45. Chen L, Lu W, Agrawal S, Zhou W, Zhang R, Chen J. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol Med. 1999;5:21-34[Medline] [Order article via Infotrieve].
46.
Teoh G, Urashima M, Ogata A, et al.
MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells.
Blood.
1997;90:1982-1992 47. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INF4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998;92:725-734[CrossRef][Medline] [Order article via Infotrieve]. 48. Hsieh JK, Chan FS, O'Connor DJ, Mittnacht S, Zhong S, Lu X. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell. 1999;3:181-193[CrossRef][Medline] [Order article via Infotrieve]. 49. Grossman SR, Perez M, Kung AL, et al. P300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell. 1998;2:405-415[CrossRef][Medline] [Order article via Infotrieve]. 50. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol. 1997;7:860-869[CrossRef][Medline] [Order article via Infotrieve]. 51. Wasylyk C, Salvi R, Argentini M, et al. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene. 1999;18:1921-1934[CrossRef][Medline] [Order article via Infotrieve]. 52. Balint E, Bates S, Vousden KH. Mdm2 binds p73 alpha without targeting degradation. Oncogene. 1999;18:3923-3929[CrossRef][Medline] [Order article via Infotrieve]. 53. Kubbutat MHG, Vousden KH. Keeping an old friend under control: regulation of p53 stability. Mol Med Today. 1998;4:250-256[CrossRef][Medline] [Order article via Infotrieve]. 54. Janicek MF, Sevin BU, Nguyen HN, Averette HE. Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines. Gynecol Oncol. 1995;59:87-92[CrossRef][Medline] [Order article via Infotrieve]. 55. Shohat O, Greenberg M, Reisman D, Oren M, Rotter V. Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. Oncogene. 1987;1:277-283[Medline] [Order article via Infotrieve]. 56. Bayever E, Haines KM, Iversen PL, et al. Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk Lymphoma. 1994;12:223-231[Medline] [Order article via Infotrieve]. 57. Prasolov VS, Chumakov PM. Antisense RNA p53 inhibits proliferation of normal and transformed cells. Mol Biol (Mosk). 1988;22:1371-1380[Medline] [Order article via Infotrieve]. 58. Iotsova V, Stehelin D. Antisense p53 provokes changes in HeLa cell growth and morphology. Eur J Cell Biol. 1995;68:122-132[Medline] [Order article via Infotrieve]. 59. Hirota Y, Horiuchi T, Akahane K. p53 antisense oligonucleotide inhibits growth of human colon tumor and normal cell lines. Jpn J Cancer Res. 1996;87:735-742[CrossRef][Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  K. Fizazi, J. Yang, S. Peleg, C. R. Sikes, E. L. Kreimann, D. Daliani, M. Olive, K. A. Raymond, T. J. Janus, C. J. Logothetis, et al. Prostate Cancer Cells-Osteoblast Interaction Shifts Expression of Growth/Survival-related Genes in Prostate Cancer and Reduces Expression of Osteoprotegerin in Osteoblasts Clin. Cancer Res., July 1, 2003; 9(7): 2587 - 2597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Seewaldt, K. Mrozek, R. Sigle, E. C. Dietze, K. Heine, D. M. Hockenbery, K. B. Hobbs, and L. E. Caldwell Suppression of p53 function in normal human mammary epithelial cells increases sensitivity to extracellular matrix-induced apoptosis J. Cell Biol., October 29, 2001; 155(3): 471 - 486. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
, or
GADD45) or in induction of apoptosis (Bax or the
PIGs genes) (reviewed in reference 3). It has been amply
demonstrated that the loss of p53 function is a key event in
tumorigenesis, and abnormalities of the p53 gene, which
generally result in inactivation of the protein, are among the most
common molecular events in human malignancies (reviewed in references 4 and 5). Moreover, in several tumor types, p53 inactivation can also
occur through complex formation with either virally encoded proteins
(SV40 T, adenovirus E1A, HPV E6) or the cellular protein
MDM2.
(which is expressed in Saos-2 cells) and impede its translational
activity,